Goldman Sachs Group Inc. Raises Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Goldman Sachs Group Inc. boosted its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 23.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 228,053 shares of the company’s stock after purchasing an additional 43,709 shares during the period. Goldman Sachs Group Inc. owned about 0.81% of Krystal Biotech worth $28,292,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Jennison Associates LLC increased its position in shares of Krystal Biotech by 112.5% during the 4th quarter. Jennison Associates LLC now owns 724,344 shares of the company’s stock valued at $89,862,000 after purchasing an additional 383,495 shares during the period. Fiera Capital Corp bought a new stake in shares of Krystal Biotech in the 4th quarter worth $1,973,000. TimesSquare Capital Management LLC bought a new stake in shares of Krystal Biotech in the 3rd quarter worth $14,272,000. Braidwell LP raised its stake in shares of Krystal Biotech by 153.2% in the 4th quarter. Braidwell LP now owns 196,200 shares of the company’s stock worth $24,341,000 after buying an additional 118,703 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Krystal Biotech by 40.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,400,142 shares of the company’s stock worth $278,416,000 after buying an additional 693,852 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Trading Up 2.1 %

Shares of KRYS stock opened at $174.82 on Monday. Krystal Biotech, Inc. has a 1-year low of $93.95 and a 1-year high of $191.78. The company has a market capitalization of $4.99 billion, a price-to-earnings ratio of 93.49 and a beta of 0.90. The stock’s fifty day simple moving average is $164.53 and its 200-day simple moving average is $147.99.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, May 6th. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.17). The firm had revenue of $45.25 million during the quarter, compared to analyst estimates of $47.37 million. During the same quarter last year, the company earned ($1.76) EPS. The company’s quarterly revenue was up 452400.0% compared to the same quarter last year. On average, sell-side analysts predict that Krystal Biotech, Inc. will post 2.06 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently commented on KRYS. William Blair reissued an “outperform” rating on shares of Krystal Biotech in a research note on Tuesday, February 27th. Citigroup boosted their target price on Krystal Biotech from $160.00 to $195.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Guggenheim boosted their target price on Krystal Biotech from $130.00 to $175.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Stifel Nicolaus reaffirmed a “buy” rating and set a $204.00 target price (up from $178.00) on shares of Krystal Biotech in a research report on Tuesday, April 16th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $200.00 target price on shares of Krystal Biotech in a research report on Monday, May 6th. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Krystal Biotech has a consensus rating of “Buy” and a consensus target price of $177.63.

Insider Buying and Selling at Krystal Biotech

In other news, Director Julian S. Gangolli sold 20,000 shares of the firm’s stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $164.13, for a total transaction of $3,282,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the transaction, the insider now directly owns 1,525,882 shares of the company’s stock, valued at $268,189,020.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Julian S. Gangolli sold 20,000 shares of the stock in a transaction on Monday, May 20th. The stock was sold at an average price of $164.13, for a total transaction of $3,282,600.00. The disclosure for this sale can be found here. Corporate insiders own 14.10% of the company’s stock.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).